Category: Research News

Theranostics has just received its latest Impact Factor for the year 2022, which is 12.4. It ranks 8th among 136 comprehensive journals worldwide in the field of medical research and experimental studies, placing it in the top tier of JCR Q1. Congratulations! Theranostics journal is dedicated to integrated research in clinical and basic medicine. It primarily publishes articles and review papers on molecular diagnostics in vivo and in vitro, tumor treatment, targeted therapy, biological therapy, nanomedicine, translational medicine, as well as basic biomedical research. Welcome to submit your manuscript to Theranostics.

  T cells play a determining role in the immunomodulation and prognostic evaluation of cancer treatments relying on immune activation. While specific biomarkers determine the population and distribution of T cells in tumours, the in situ activity of T cells is less studied. Here we designed T-cell-targeting fusogenic liposomes to regulate and quantify the activity of T cells by exploiting their surface redox status as a chemical target. The T-cell-targeting fusogenic liposomes equipped with 2,2,6,6-tetramethylpiperidine (TEMP) groups neutralize reactive oxygen species protecting T cells from oxidation-induced loss of activity. Meanwhile, the production of paramagnetic 2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO) radicals allows magnetic

  Professor Shawn Chen Xiaoyuan, Nasrat Muzayyin Professor in Medicine and Technology, and Director of the Nanomedicine Translational Research Programme at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), and a team of researchers, have developed potent yet low-inflammatory mRNA cancer vaccine vectors-; non-harmful vehicles that deliver the DNA instructions into cells, which in turn trigger protective immunity against the cancer cells. Instead of LNPs, they applied polymers as the carrier for cancer mRNA vaccines. As carriers, these polymers can similarly deliver vaccine antigens, proteins, and drugs to the site of action, with lower inflammatory

Read more here: CNA Insider NUS Medicine. in partnership with Channel NewsAsia, has developed a CNAInsider documentary series to tell the story of the School’s research work. In this series. find out how the Translational Research Programmes (TRPs) at NUS Medicine are addressing priority health concerns of Singapore and beyond. The Nanomedicine TRP: Milk as medicine for gut diseases People who have suffered from inflammatory bowel disease will know the discomfort and inconvenience it can cause, with symptoms including abdominal pain. diarrhoea and bloody stools. Treatment-usually with antibiotics, anti-inflammatory drugs or immunosuppressive drugs-comes with side effects. Antibiotics. for instance. can

Highly cited NUS researcher under Chemistry & Materials Science : Professor Chen Xiaoyuan, Shawn Clinical Imaging Research Centre, Department of Diagnostic Radiology, NUS Yong Loo Lin School of Medicine Department of Biomedical Engineering, NUS College of Design and Engineering Read more: NUSnews  

Award Winner Dr Zhang Jingjing Principal Investigator, Nanomedicine Translational Research Programme, NUS Yong Loo Lin School of Medicine Read more